Globenewswire… Read the rest “Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™”
Globenewswire… Read the rest “Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™”
Globenewswire… Read the rest “Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum”
ALZ Forum… Read the rest “Elusive or Not, Aβ Oligomers Are in BioPharma Crosshairs”
Alzheimer’s News Today… Read the rest “Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports”
Globenewswire… Read the rest “Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference”
EconoTimes… Read the rest “Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference”
Globenewswire… Read the rest “Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery”
Globe Newswire… Read the rest “Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th”
Globe Newswire… Read the rest “Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate”
Alzheimer’s Today… Read the rest “FDA Places CT1812, Potential Disease-Modifying Alzheimer’s Treatment, on Fast Track”
MPR… Read the rest “First-in-Class Alzheimer’s Drug Gets Fast-Tracked by FDA”
Clinical Leader… Read the rest “Cognition Therapeutics Receives Fast Track Designation From U.S. FDA For First-In-Class Alzheimer’s Candidate, CT1812”
Globenewswire… Read the rest “Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812”
Globe Newswire… Read the rest “Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day”
Globe Newswire… Read the rest “Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting”
Globe Newswire… Read the rest “Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors”
Pittsburgh Business Times… Read the rest “Lazard exec joins Cognition Therapeutics board”
Globe Newswire… Read the rest “Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference”
Globe Newswire… Read the rest “Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate”
FairHerald… Read the rest “Cognition Therapeutics $6.50 million Financing”
click here… Read the rest “Cognition Therapeutics aims to stop memory loss with breakthrough Alzheimer’s drug”
click here… Read the rest “Cognition Therapeutics initiates U.S. testing for Alzheimer’s Drug”
click here… Read the rest “Cognition Therapeutics Initiates US Clinical Testing Of CT1812, A Novel Small Molecule For The Potential Treatment Of Alzheimer’s Disease”
click here… Read the rest “Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer’s disease”
click here… Read the rest “Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting”
click here… Read the rest “CogRX: Society for Neuroscience 2016 Annual Meeting Nanosymposium Explores Potential of “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics””
click here… Read the rest “Form D To Observe: Cognition Therapeutics $3.00 million Financing. Kenneth I Moch Submitted Nov 30 Filing”
click here… Read the rest “CogRX: 1st Alzheimer’s Patient Dosed in Clinical Trial of Amyloid Beta ‘Displacer’”
click here… Read the rest “CogRx sees Lilly solanezumab results support for its unique mechanism for Alzheimer’s disease treatment”
click here… Read the rest “Cognition Therapeutics Sees Lilly Solanezumab Clinical Trial Results as Support for its Unique Mechanism for Treatment of Alzheimer’s Disease”
click here… Read the rest “Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812”
click here… Read the rest “Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO”
click here… Read the rest “Cognition Therapeutics: Cognitive impairment pipeline market analysis H2 2016 examined in new market research report”
click here… Read the rest “Cognition Therapeutics launching clinical trials for Alzheimer’s drug in Australia”
click here… Read the rest “Cognition Therapeutics: Five things to know today”
click here… Read the rest “Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease”
click here… Read the rest “Drug development is on the rise in Pittsburgh, but there’s room to grow”
Named after Tech Coast Angels’ inspiring co-founder, the annual award goes to most outstanding and innovative early stage company
May 18, 2016 – IRVINE, Calif. – Tech Coast Angels (TCA) today announced that the Angel Capital Association (ACA) had awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia.… Read the rest “Cognition Therapeutics Receives Prestigious Luis Villalobos Award from Angel Capital Association”
Click here… Read the rest “Cognition Therapeutics Receives Prestigious Luis Villalobos Award from Angel Capital Association”
click here… Read the rest “Angels hail Pittsburgh company Cognition Therapeutics as most innovative startup”
click here… Read the rest “Pittsburgh Life Sciences Greenhouse Portfolio Company Cognition Therapeutics Wins Angel Capital Association’s Luis Villabos Award”
Southern California Angel Network Surpasses Previous Records for Both Investments and Activity
IRVINE, Calif. January 29, 2015 Tech Coast Angels (TCA) invested a total of $16,373,337 in 61 total deals in Calendar Year 2014. The angel network announced that 2014 was the most active year since the networks inception in 1997 for number of deals funded, and capital raised was also the largest ever.… Read the rest “Tech Coast Angels Invested Best Ever $16.37 Million in 2014”
Largest Angel Network in United States Invests in 17 Innovative Companies Across Broad Range of Industries
IRVINE, Calif. – August 15, 2012 – Tech Coast Angels (TCA) raised more than $10 million of total investment in 17 innovative companies, including $4,571,000 of direct TCA investment, during the first half of 2012 via the group’s five networks (Los Angeles, Orange County, San Diego, Central Coast, and Inland Empire).… Read the rest “Tech Coast Angels Invests More Than $4.5 Million in 1H 2012”
IRVINE, Calif., February 22, 2011 Tech Coast Angels (TCA), the nations largest angel investment network, today announced it funded 31 investments, including 12 new deals and 19 follow-on investments in a broad range of start-up businesses, demonstrating its angel investment leadership.… Read the rest “TECH COAST ANGELS FUNDS 31 DEALS IN 2010 AND HIGHLIGHTS THREE PROFITABLE EXITS”
PITTSBURGH, Jan. 20, 2011 /PRNewswire/ — Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer’s, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status.… Read the rest “TCA portfolio company Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer’s Disease Drug Treatment Program”
30 TCA Portfolio Companies Secure More Than 75M in 2008